Literature DB >> 30910370

Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient.

Matthew R D'Costa1, Nelson S Winkler2, Dawn S Milliner3, Suzanne M Norby1, LaTonya J Hickson1, John C Lieske4.   

Abstract

We report a case of systemic oxalosis involving the eyes and joints due to long-term use of high-dose vitamin C in a patient receiving maintenance peritoneal dialysis (PD). This 76-year-old woman with autosomal dominant polycystic kidney disease underwent living unrelated kidney transplantation 10 years earlier. The transplant failed 6 months before presentation, and she initiated hemodialysis therapy before transitioning to PD therapy 4 months later. During the month before presentation, the patient noted worsening arthralgias and decreased vision. Ophthalmologic examination revealed proliferative retinopathy and calcium oxalate crystals. Plasma oxalate level was markedly elevated at 187 (reference range, <1.7) μmol/L, and urine oxalate-creatinine ratio was high (0.18mg/mg). The patient reported taking up to 4g of vitamin C per day for several years. Workup for causes of primary and secondary hyperoxaluria was otherwise negative. Vitamin C use was discontinued, and the patient transitioned to daily hemodialysis for 2 weeks. Plasma oxalate level before the dialysis session decreased but remained higher (30-53μmol/L) than typical for dialysis patients. Upon discharge, the patient remained on thrice-weekly hemodialysis therapy with stabilized vision and improved joint symptoms. This case highlights the risk of high-dose vitamin C use in patients with advanced chronic kidney disease, especially when maintained on PD therapy.
Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ascorbic acid; case report; dialytic clearance; oxalate removal; oxalosis; peritoneal dialysis (PD); retinopathy; supplements; vision loss; vitamin C

Mesh:

Substances:

Year:  2019        PMID: 30910370      PMCID: PMC6708738          DOI: 10.1053/j.ajkd.2019.01.022

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  21 in total

1.  Peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 during continuous ambulatory peritoneal dialysis.

Authors:  M Mydlík; K Derzsiová; J Svác; P Dlhopolcek; E Zemberová
Journal:  Artif Organs       Date:  1998-09       Impact factor: 3.094

2.  Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.

Authors:  K Ono
Journal:  Clin Nephrol       Date:  1986-11       Impact factor: 0.975

Review 3.  An update on primary hyperoxaluria.

Authors:  Bernd Hoppe
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

4.  The non-oxidative degradation of ascorbic acid at physiological conditions.

Authors:  G L Simpson; B J Ortwerth
Journal:  Biochim Biophys Acta       Date:  2000-04-15

5.  Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

Authors:  Xiaojing Tang; Nikolay V Voskoboev; Stacie L Wannarka; Julie B Olson; Dawn S Milliner; John C Lieske
Journal:  Am J Nephrol       Date:  2014-04-26       Impact factor: 3.754

6.  Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.

Authors:  Paul E Marik; Vikramjit Khangoora; Racquel Rivera; Michael H Hooper; John Catravas
Journal:  Chest       Date:  2016-12-06       Impact factor: 9.410

7.  CRYSTALLINE RETINOPATHY FROM HYPEROXALURIA: LONG-TERM FOLLOW-UP.

Authors:  Amit A Sangave; Matthew D Gearinger; David A Diloreto
Journal:  Retin Cases Brief Rep       Date:  2017 Winter

8.  Determinants of 24-hour urinary oxalate excretion.

Authors:  Eric N Taylor; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

9.  Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis.

Authors:  Robert Deicher; Farzad Ziai; Antje Habicht; Christian Bieglmayer; Martin Schillinger; Walter H Hörl
Journal:  Nephrol Dial Transplant       Date:  2004-09       Impact factor: 5.992

10.  Chapter 3: Use of ESAs and other agents to treat anemia in CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-08
View more
  4 in total

Review 1.  Food as medicine: targeting the uraemic phenotype in chronic kidney disease.

Authors:  Denise Mafra; Natalia A Borges; Bengt Lindholm; Paul G Shiels; Pieter Evenepoel; Peter Stenvinkel
Journal:  Nat Rev Nephrol       Date:  2020-09-22       Impact factor: 28.314

2.  Pathophysiology and Treatment of Enteric Hyperoxaluria.

Authors:  Celeste Witting; Craig B Langman; Dean Assimos; Michelle A Baum; Annamaria Kausz; Dawn Milliner; Greg Tasian; Elaine Worcester; Meaghan Allain; Melissa West; Felix Knauf; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-08       Impact factor: 8.237

3.  Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report.

Authors:  Shinobu Takayasu; Aya Kamba; Kazutaka Yoshida; Ken Terui; Yutaka Watanuki; Noriko Ishigame; Satoru Mizushiri; Tetsu Tomita; Kazuhiko Nakamura; Norio Yasui-Furukori; Makoto Daimon
Journal:  BMC Nephrol       Date:  2020-05-01       Impact factor: 2.388

4.  Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding.

Authors:  Yaru Xing; Bing Zhao; Lin Yin; Mingquan Guo; Huichun Shi; Zhaoqin Zhu; Lin Zhang; Juan He; Yun Ling; Menglu Gao; Hongzhou Lu; Enqiang Mao; Lijun Zhang
Journal:  J Pharm Biomed Anal       Date:  2021-01-27       Impact factor: 3.935

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.